- Home
- VRAX vs QLGN Comparison
VRAX vs QLGN Comparison
Compare VRAX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- QLGN
- Stock Information
- Founded
- VRAX 2013
- QLGN 1996
- Country
- VRAX United Kingdom
- QLGN United States
- Employees
- VRAX N/A
- QLGN N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- VRAX Health Care
- QLGN Health Care
- Exchange
- VRAX Nasdaq
- QLGN Nasdaq
- Market Cap
- VRAX 4.4M
- QLGN 4.7M
- IPO Year
- VRAX 2022
- QLGN N/A
- Fundamental
- Price
- VRAX $0.95
- QLGN $2.80
- Analyst Decision
- VRAX Strong Buy
- QLGN
- Analyst Count
- VRAX 1
- QLGN 0
- Target Price
- VRAX $3.00
- QLGN N/A
- AVG Volume (30 Days)
- VRAX 155.0K
- QLGN 2.5M
- Earning Date
- VRAX 02-05-2025
- QLGN 07-21-2025
- Dividend Yield
- VRAX N/A
- QLGN N/A
- EPS Growth
- VRAX N/A
- QLGN N/A
- EPS
- VRAX N/A
- QLGN N/A
- Revenue
- VRAX $6,331.00
- QLGN N/A
- Revenue This Year
- VRAX $217,274.83
- QLGN N/A
- Revenue Next Year
- VRAX N/A
- QLGN N/A
- P/E Ratio
- VRAX N/A
- QLGN N/A
- Revenue Growth
- VRAX N/A
- QLGN N/A
- 52 Week Low
- VRAX $0.74
- QLGN $2.60
- 52 Week High
- VRAX $9.00
- QLGN $13.43
- Technical
- Relative Strength Index (RSI)
- VRAX 51.51
- QLGN 35.34
- Support Level
- VRAX $0.86
- QLGN $2.77
- Resistance Level
- VRAX $1.10
- QLGN $3.29
- Average True Range (ATR)
- VRAX 0.11
- QLGN 0.54
- MACD
- VRAX 0.01
- QLGN -0.06
- Stochastic Oscillator
- VRAX 35.48
- QLGN 5.38
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.